Table 2.
Local control: univariate analysis for all 70 patients
| Characteristic | No. of patients (%) | 5-yr LC | p value | 5-yr DMFS | p value |
|---|---|---|---|---|---|
| Entire cohort | 70 | 43% | 55% | ||
| Sex | |||||
| Male | 50 (71) | 45% | 0.91 | 48% | 0.19 |
| Female | 20 (29) | 40% | 74% | ||
| Tumor size | |||||
| ≤ 5 cm | 49 (82)* | 55% | 0.05 | 53% | 0.34 |
| > 5 cm | 11(18) | 0% | 0% | ||
| Site | |||||
| Scalp | 39 (56) | 46% | .50 | 53% | 0.26 |
| Face/ear | 31 (44) | 31% | 58% | ||
| Satellites at presentation | |||||
| No | 38 (54) | 49% | 0.08 | 67% | 0.003 |
| Yes | 32 (46) | 38% | 35% | ||
| Nodal disease at diagnosis | |||||
| No | 63 (90) | 39% | 0.19 | 56% | 0.78 |
| Yes | 7 (10) | 83% | 48% | ||
| Local therapy | |||||
| Surgery alone | 20 (29) | 25% | 0.0003 | 69% | 0.03 |
| RT alone | 27 (39) | 22% | 24% | ||
| Surgery + RT | 23 (33) | 84% | 67% | ||
| Local therapy | |||||
| Single modality (S or RT) | 24% | 0.0001 | 48% | 0.19 | |
| Combined modality | 84% | 67% | |||
| Surgical resection margin** | |||||
| Positive/uncertain | 23 (53) | 62% | 0.55 | 72% | 0.81 |
| Negative | 20 (47) | 46% | 63% | ||
| Neoadjuvant chemotherapy | |||||
| No | 37 (53) | 41% | 0.99 | 69% | 0.06 |
| Yes | 33 (47) | 44% | 38% | ||
| Adjuvant chemotherapy | |||||
| No | 50 (71) | 34% | 0.04 | 60% | 0.53 |
| Yes | 20 (29) | 63% | 45% | ||
| Any chemotherapy (neoadjuvant, adjuvant, or both) | |||||
| No | 26 (37) | 29% | 0.11 | 72% | 0.16 |
| Yes | 44 (63) | 52% | 45% | ||
| Total scalp RT | |||||
| No | 49 (70) | 44% | 0.56 | n/a | |
| Yes | 21 (30) | 39% | |||
cm= centimeter; RT= radiation therapy; LC=local control rate; DMFS=distant metastasis free survival; CMT=combined modality local therapy (surgery + RT or RT + surgery)
*
Tumor size was not available for 10 patients.
**
Only includes the 43 pts who received surgery (with or without RT) for primary local therapy